Hepatitis C virus (HCV) chronically infects 0.5-3% of the world population. A large group of patients develop cirrhosis and its complications. Since 2011, telaprevir and boceprevir are used, improving the disease evolution. One of the main side effects of these drugs is skin eruption. We report a 53-year-old patient with cirrhosis due to HCV who started the classic treatment associated with telaprevir. In the ninth week, he presented a severe rash that required the interruption of this drug. We emphasize the importance of early recognition and appropriate management of adverse skin reaction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612548PMC
http://dx.doi.org/10.1159/000439264DOI Listing

Publication Analysis

Top Keywords

cutaneous eruption
4
eruption telaprevir
4
telaprevir hepatitis
4
hepatitis virus
4
virus hcv
4
hcv chronically
4
chronically infects
4
infects 05-3%
4
05-3% population
4
population large
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!